Nautilus Biotechnolgy Inc.

NAUT | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.98

+$0.03 (+2.65%)

Sep 22, 2026, 12:48 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.65%

(1D)

Rating

Updated: Sep 19, 2026

30.8

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $125.19M

1D Range

0.95 0.99

52W Range

0.69 4.31

Valuation (TTM)

PE -2.11

PB 0.93

EV/EBITDA -1.23

Valuation (NTM)

Forward PE N/A

Forward PEG -1.08

Price Target $2.50

Cash Flow

FCF Yield -42.7%

SBC Adj. FCF Yield -47.2%

SBC Impact -10.6%

Margins

Gross Margin -919.5%

Operating Margin -33043.7%

FCF Margin -27295.3%

Growth (CAGR)

Revenue 3Y | 5Y 150.0% | 100.0%

Dil EPS 3Y | 5Y 10.8% | 1.0%

FCF 3Y | 5Y 7.1% | -1.1%

Returns

ROA -34.5%

ROE -37.6%

ROIC -39.5%

Financial Health

Net Cash

$84.03M

Current Ratio 10.14

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. Th...

Sector Healthcare

Industry Biotechnology

Employees 127

IPO Date Aug 6, 2020

Website www.nautilus.bio

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Oct 27, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$2.50

Upside

+155.10%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞